Authors: Wahedi HM, Ahmad S, Abbasi SW PMID: 32345140 DOI: 10.1080/07391102.2020.1762743 Abstract The pandemic coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a great threat to public health. Currently, no potent medicine is available to treat COVID-19. Quest for new drugs especially from natural plant sources is an area of [...]

Authors: Bharath LP, Agrawal M, McCambridge G, Nichols DA, Hasturk H, Liu J et al. PMID: 32402267 PMCID: PMC7217133 DOI: 10.1016/j.cmet.2020.04.015 Abstract Age is a non-modifiable risk factor for the inflammation that underlies age-associated diseases; thus, anti-inflammaging drugs hold promise for increasing health span. Cytokine profiling and bioinformatic analyses showed that Th17 cytokine production differentiates [...]

Authors: Banerjee A, Pasea L, Harris S, Gonzalez-Izquierdo A PMID: 32405103 PMCID: PMC7217641 DOI: 10.1016/S0140-6736(20)30854-0 Abstract Background: The medical, societal, and economic impact of the coronavirus disease 2019 (COVID-19) pandemic has unknown effects on overall population mortality. Previous models of population mortality are based on death over days among infected people, nearly all of whom [...]

Authors: Wang J, Najizadeh N, Moore EE, McIntyre RC, Moore PK, Veress LA PMID: 32267998 PMCID: PMC7262152 DOI: 10.1111/jth.14828 Abstract A prothrombotic coagulopathy is commonly found in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS). A unique feature of COVID-19 respiratory failure is a relatively preserved lung compliance and high Alveolar-arterial oxygen gradient, [...]

The pathogenesis of a COVID-19 respiratory infection, in a major way, is related to what is referred to as the cytokine storm [cytokine storm syndrome (CSS, hypercytokinemia, etc.], i.e., it is a hyper-inflammatory response.

Authors: Spinelli FR, Conti F, Gadina M PMID: 32385052 DOI: 10.1126/sciimmunol.abc5367 Abstract JAK kinase inhibitors are being investigated as a way of managing cytokine storm in severe COVID-19 patients. Keywords: SARS-CoV-2, JAK inhibitors, COVID-19 Source: https://pubmed.ncbi.nlm.nih.gov/32385052/ Archive: https://archive.ph/Jwcrd

Auhtors: Duan F, Mei C, Yang L, Zheng J, Lu H, Xia Y, et al. PMID: 32382009 PMCID: PMC7206016 DOI: 10.1038/s41598-020-64880-x Abstract Vitamin K2 has been shown to exert remarkable anticancer activity. However, the detailed mechanism remains unclear. Here, our study was the first to show that Vitamin K2 significantly promoted the glycolysis in bladder [...]

Authors:LLie PC, Stefanescu S, Smith L. PMID:PMC7202265 DOI: 10.1007/s40520-020-01570-8 AbstractWHO declared SARS-CoV-2 a global pandemic. The present aim was to propose an hypothesis that there is a potential association between mean levels of vitamin D in various countries with cases and mortality caused by COVID-19. The mean levels of vitamin D for 20 European countries [...]

Authors: Patterson BK, seethamraju H, Dhody K, Corley MJ, Pang AP PMID: 32511656 PMCID: PMC7277012 DOI: 10.1101/2020.05.02.20084673 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is now pandemic with nearly three million cases reported to date. Although the majority of COVID-19 patients experience only mild or moderate [...]

Authors: Dayer MR doi: 10.20944/preprints202005.0020.v1 Abstract The disease of COVID-19 comprises the most serious against human health worldwide with a high rate of virulence and mortality. The disease is caused by the 2019-nCoV virus from the beta coronavirus family. The virus makes use of its surface glycoprotein named S protein or spike to enter the [...]